Loading…
Swedish medtech maker of surgical workflow, sterilization and acute cardiopulmonary/critical care equipment for hospitals.
Swedish medtech maker of surgical workflow, sterilization and acute cardiopulmonary/critical care equipment for hospitals.
Sells long-life hospital equipment, then earns again from service contracts, spare parts and single-use consumables used with it, so the installed base brings steady income beyond new orders. Hospital budgets decide the timing of big equipment purchases. The investor Carl Bennet, through his holding company, is the controlling shareholder.
In one line: A Swedish Baxter International/Stryker hybrid.
Moat: narrow (installed base, switching costs, regulatory licence). Long-life hospital capital equipment creates service/upgrade lock-in, though execution/quality issues have hurt trust.
Headquarters: Gothenburg, Sweden · Founded: 1904 · Employees: 12,118
Size Getinge (GETI-B.ST) is a Sweden Health Care company (Medical Specialties) with a market value of $7.73B, the 37th largest of 221 Sweden companies the cockpit tracks. Shares closed at SEK 277.80 on 6 Nov 2026.
Performance Over six months the shares gained 45.5%, against +30.6% for the median peer and +8.2% for the Sweden market (cap-weighted) — 8th highest of 21 in its peer set.
Growth Revenue fell 3.9% over the last twelve months (peer median +3.7%); the operating margin is 13.9% (peer median 14.9%).
Valuation It trades at 21.0× forward earnings against a peer median of 19.8× (10th most expensive of 20).
Price implies For today's price to make sense, revenue must grow about 5% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.5 points above its cost of capital (6.8% WACC).
Next results Next results expected around 26 Jan 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 34.5B | SEK 35.0B | SEK 34.8B | SEK 31.8B | SEK 28.3B |
| Revenue growth | — | +1% | +9% | +12% | — |
| Gross profit | SEK 15.8B | SEK 15.4B | SEK 15.0B | SEK 13.4B | SEK 12.3B |
| EBITDA | SEK 6.87B | SEK 6.80B | SEK 6.19B | SEK 5.91B | SEK 5.63B |
| Net income | SEK 2.83B | SEK 2.26B | SEK 1.64B | SEK 2.41B | SEK 2.49B |
| Free cash flow | SEK 4.32B | SEK 2.63B | SEK 3.27B | SEK 1.60B | SEK 2.23B |
| Capital expenditure | SEK 1.20B | SEK 1.31B | SEK 1.31B | SEK 1.35B | SEK 1.14B |
| Total debt | SEK 11.2B | SEK 10.9B | SEK 10.7B | SEK 8.08B | SEK 5.82B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Getinge GETI-B.ST | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% |
| Stryker SYK | $124B | +14% | +8% | 25% | 20.4× | 10.6% |
| Baxter International BAX | $13.3B | +43% | +5% | 6% | 12.6× | 12.7% |
| Steris STE | $24.6B | +22% | +8% | 20% | 21.4× | 13.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | GETI-B.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.3% | +9.0% | 8th highest of 21 |
| 6-month return | +45.5% | +30.6% | 8th highest of 21 |
| Distance from 52-week high | -1.8% | -10.1% | highest of 21 |
| Revenue growth (TTM) | -3.9% | +3.7% | 2nd lowest of 21 |
| Operating margin | 13.9% | 14.9% | 11th highest of 21 |
| Forward P/E | 21.0× | 19.8× | 10th most expensive of 20 |
| Growth the price implies (Req g, 7 yrs) | 4.7% | 11.0% | 4th least demanding of 20 |
| Growth delivered (Del g) | +3.2% | +10.0% | 5th lowest of 20 |
| Hurdle (Req g minus delivered) | +1.5 pp | +0.9 pp | 10th most demanding of 20 |
| ROIC minus cost of capital | +2.5 pp | +2.6 pp | 11th highest of 21 |
| EV / EBITDA | 12.2× | 15.6× | 4th cheapest of 18 |
| Net debt / EBITDA | 1.2× | 0.9× | 8th most indebted of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Getinge GETI-B.ST | Sweden | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% | +3.2% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% | +15.7% |
| Cochlear COH.AX | Australia | $7.05B | +55% | -1% | 13% | 29.4× | 24.1% | +9.3% |
| Lantheus LNTH | United States | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% | +35.3% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% | +4.6% |
| Teleflex TFX | United States | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% | -4.7% |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% | +12.6% |
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% | +18.8% |
| Globus Medical GMED | United States | $9.54B | -9% | +20% | 22% | 14.1× | 5.5% | +30.1% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 37% | 38.5× | 8.7% | +40.1% |
| Insulet PODD | United States | $10.2B | -5% | +26% | 18% | 19.5× | 10.3% | +24.5% |
| Bio-Rad Laboratories BIO | United States | $10.3B | +50% | +1% | 9% | 35.7× | 26.5% | +0.3% |
| Qiagen QGEN | United States | $10.4B | +52% | +3% | 25% | 19.8× | 8.8% | +2.2% |
| Avantor AVTR | United States | $10.5B | +86% | +1% | 8% | 17.7× | 16.1% | +0.5% |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |